Enliven
ELVNEnliven Therapeutics, Inc. Price (ELVN)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
47,072,532
(32.4263)%Income Statement Summary
| Revenue | |
| Cost of Revenue | |
| Gross Profit | |
| Operating Expenses | |
| Operating Income | |
| Other Expenses | |
| Net Income |
Income Statement
Enliven Therapeutics, Inc.Currency: USD
| YEAR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Revenue |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
0.00
+0% |
|||||||||||
| Cost of Revenue | |||||||||||||||||||
| Cost of Revenue | 0.00 | 0.00 | 33,000.00 | 97,000.00 | 99,000.00 | 622,000.00 | 297,000.00 | 0.00 | |||||||||||
| Gross Profit | |||||||||||||||||||
| Gross Profit |
0.00
+0% |
0.00
+0% |
-33,000.00
+0% |
-97,000.00
+194% |
-99,000.00
+2% |
-622,000.00
+528% |
-297,000.00
-52% |
0.00
+0% |
|||||||||||
| Gross Profit Ratio | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||||
| Operating Expenses | |||||||||||||||||||
| Research and Development | 7,918,000.00 | 8,239,000.00 | 19,009,000.00 | 8,240,000.00 | 20,474,000.00 | 31,022,000.00 | 64,574,000.00 | 80,778,000.00 | |||||||||||
| General and Administrative | 0.00 | 2,438,000.00 | 5,107,000.00 | 1,078,000.00 | 4,288,000.00 | 7,769,000.00 | 18,955,000.00 | 23,776,000.00 | |||||||||||
| Selling, General & Admin... | 987,000.00 | 2,438,000.00 | 5,074,000.00 | 1,078,000.00 | 4,288,000.00 | 7,769,000.00 | 18,955,000.00 | 23,776,000.00 | |||||||||||
| Selling & Marketing Exp... | 0.00 | 0.00 | -33,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Depreciation and Amortiz... | 0.00 | -660,000.00 | 33,000.00 | 97,000.00 | 115,000.00 | 215,000.00 | 297,000.00 | 0.00 | |||||||||||
| Other Expenses | 0.00 | 0.00 | 0.00 | -9,679,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Total Operating Expenses | 8,905,000.00 | 10,677,000.00 | 24,083,000.00 | 9,318,000.00 | 24,762,000.00 | 38,791,000.00 | 83,529,000.00 | 104,554,000.00 | |||||||||||
| Cost and Exponses | 8,905,000.00 | 10,677,000.00 | 24,116,000.00 | 9,318,000.00 | 24,762,000.00 | 38,791,000.00 | 83,529,000.00 | 0.00 | |||||||||||
| Operating Income | |||||||||||||||||||
| Operating Income |
-8,905,000.00
+0% |
-10,677,000.00
+20% |
-24,116,000.00
+126% |
-9,318,000.00
-61% |
-24,762,000.00
+166% |
-38,791,000.00
+57% |
-83,529,000.00
+115% |
-104,554,000.00
+25% |
|||||||||||
| Operating Income Ratio | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||||
| Other Income and Exp... | |||||||||||||||||||
| Interest Income | 0.00 | 0.00 | 578,000.00 | 31,000.00 | 22,000.00 | 1,129,000.00 | 11,967,000.00 | 14,891,000.00 | |||||||||||
| Interest Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Total Other Income/Exp... | 9,126,000.00 | -660,000.00 | 653,000.00 | -9,648,000.00 | 22,000.00 | 1,129,000.00 | 11,945,000.00 | 15,298,000.00 | |||||||||||
| EBITDA | |||||||||||||||||||
| EBITDA | 221,000.00 | -11,337,000.00 | -23,430,000.00 | -9,273,000.00 | -24,647,000.00 | -38,576,000.00 | -81,932,000.00 | -104,554,000.00 | |||||||||||
| EBITDA ratio | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||||
| Income Before Tax | |||||||||||||||||||
| Income Before Tax | 221,000.00 | -11,337,000.00 | -23,463,000.00 | -18,966,000.00 | -24,740,000.00 | -37,662,000.00 | -71,584,000.00 | -89,256,000.00 | |||||||||||
| Income Before Tax Ratio | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||||
| Income Tax Expense | |||||||||||||||||||
| Income Tax Expense | 221,000.00 | -821,141.00 | 653,000.00 | -31,000.00 | -22,000.00 | 88,000.00 | 0.00 | -232,000.00 | |||||||||||
| Net Income | |||||||||||||||||||
| Net Income | 0.00
+0% |
-11,337,000.00
+0% |
-23,463,000.00
+107% |
-18,935,000.00
-19% |
-24,718,000.00
+31% |
-37,750,000.00
+53% |
-71,584,000.00
+90% |
-89,024,000.00
+24% |
|||||||||||
| Net Income Ratio | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | (0.00%) | |||||||||||
| Earning Per Share | |||||||||||||||||||
| Basic EPS | 0.00 | -2.62 | -5.43 | -14.14 | -3.17 | -6.03 | -2.01 | -1.89 | |||||||||||
| Diluted EPS | 0.00 | -2.62 | -5.43 | -14.14 | -3.17 | -6.03 | -2.01 | -1.89 | |||||||||||
| Share Outstanding | |||||||||||||||||||
| Basic Share Outstanding | 4,320,116.00 | 4,320,116.00 | 4,320,116.00 | 3,481,182.00 | 7,814,000.00 | 6,248,548.00 | 35,546,215.00 | 47,072,532.00 | |||||||||||
| Diluted Share Outstanding | 4,320,116.00 | 4,320,116.00 | 4,320,116.00 | 3,481,182.00 | 7,814,536.00 | 6,248,548.00 | 35,546,215.00 | 47,072,532.00 | |||||||||||